Atrial natriuretic peptide preserves endothelial function during intimal hyperplasia

Area of Science:

• Cardiovascular Research
• Endocrinology
• Pharmacology

Background:

• Atrial and C-type natriuretic peptides (ANP and CNP) exhibit antiproliferative effects in vitro.
• CNP has shown benefits in early atherosclerosis in vivo, but ANP's in vivo antiproliferative capacity remains unclear.
• This study investigates the in vivo effects of ANP and CNP on endothelial dysfunction and intimal thickening.

Purpose of the Study:

• To compare the effects of chronic in vivo administration of ANP and CNP on endothelial dysfunction and intimal thickening.
• To determine if ANP possesses antiproliferative effects in vivo similar to CNP.
• To assess the impact of peri-arterial natriuretic peptides on vascular smooth muscle cell proliferation and endothelial function.

Main Methods:

• Non-occlusive collars were applied to rabbit carotid arteries.
• Collars were filled with saline vehicle, ANP, or CNP (1 or 10 microM) and peptides were infused via mini-pump (1 or 10 fmol/h).
• Endothelium-dependent and -independent vasorelaxation, and intimal hyperplasia were assessed after 7 days. Intraluminal administration was also tested.

Main Results:

• Peri-arterial ANP and CNP restored endothelium-dependent vasorelaxation impaired by collars.
• Neither peptide altered endothelium-independent vasorelaxation.
• Peri-arterial ANP/CNP did not prevent collar-induced intimal hyperplasia, but intraluminal CNP reduced neointima formation by 16%.

Conclusions:

• Chronic peri-arterial ANP or CNP administration effectively prevented endothelial dysfunction, a key feature of atherosclerosis and restenosis.
• Differences in in vitro effects on vascular smooth muscle cells may explain CNP's superior in vivo effect on intimal hyperplasia.
• CNP demonstrated a greater capacity to reduce neointima formation when delivered directly into the artery lumen.